Back to search

Article

How the HTAR will contribute to a value-based decision making for medicinal products across the EU

2025-08-06

Abstract excerpt

The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025. HTAR includes some core domains such as Joint Clinical Assessment (JCA), which refers to relative effectiveness assessment of new technologies that have...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c9aaa627-b1eb-5325-8091-8f9d4f826ee3
DOI
10.22541/au.175444754.45859770/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
How the HTAR will contribute to a value-based decision making for medicinal products across the EUDOI 10.22541/au.175444754.45859770/v1
Time to Patients’ Access to New Medicines in Greece: Evaluation of Health Technology Assessment (HTA) Process from July 2018 until January 2021.Semantic proximity
Real World Evidence – Current Developments and PerspectivesSemantic proximity
Launch Sequencing of Pharmaceuticals with Multiple Therapeutic Indications: Evidence from Seven CountriesSemantic proximity
Methodological Challenges in Dutch HTA of Non-Oncological Orphan Drugs: A Retrospective Analysis and Price Comparison Using different Pricing ModelsSemantic proximity
Health Technology Assessment of Diagnostic Tests: A state of the art review of methods guidance from international organisationsSemantic proximity
EU’s Medical Device Expert Panels: Analysis of Membership and Published Clinical Evaluation Consultation Procedure (CECP) ResultsSemantic proximity
Assessing the Value of Integrated Evidence Approaches in Drug DevelopmentSemantic proximity
U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018Semantic proximity
Quantifying the Dual Value and Governance Risks of Early Access Programs in Oncology: A Single-Centre Analysis and National Policy FrameworkSemantic proximity
Features, process and methods of early health technology assessment to inform developers of health technologies : a proposed framework and application to diagnostic technologiesSemantic proximity
The costs and benefits of an early access scheme for oncology medicines in IrelandSemantic proximity
Designing and Resourcing European Medical Affairs Under the EU HTA Regulation: A Market Complexity Index for Hub-and-Spoke StructuresSemantic proximity
Select a neighboring publication to make it the new centre.